Immunomodulatory News and Research

RSS
Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

SIR issues position statement to determine safety, effectiveness of interventional M.S. treatment

SIR issues position statement to determine safety, effectiveness of interventional M.S. treatment

NIDA grants Selecta Biosciences $3M to develop nicotine vaccine for smoking cessation and relapse prevention

NIDA grants Selecta Biosciences $3M to develop nicotine vaccine for smoking cessation and relapse prevention

Carfilzomib could become new option for patients with relapsed myeloma, IMF says

Carfilzomib could become new option for patients with relapsed myeloma, IMF says

IDC secures $32 million in Series B financing

IDC secures $32 million in Series B financing

Elan total revenue increases 10% to $579.4 million for first half of 2010

Elan total revenue increases 10% to $579.4 million for first half of 2010

Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial

Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

Study evaluates effect of Viusid on oxidative stress, cytokine parameters in patients with CHC

Study evaluates effect of Viusid on oxidative stress, cytokine parameters in patients with CHC

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

Patients with transformed lymphoma show positive response to lenalidomide: Research

Patients with transformed lymphoma show positive response to lenalidomide: Research

Biogen Idec to join global MS community to commemorate the second annual World MS Day

Biogen Idec to join global MS community to commemorate the second annual World MS Day

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

IRX Therapeutics and Japan's NCRC collaborate to evaluate peptide-based cancer vaccines

IRX Therapeutics and Japan's NCRC collaborate to evaluate peptide-based cancer vaccines

Tel Aviv scientist uncovers a new way of detecting multiple sclerosis

Tel Aviv scientist uncovers a new way of detecting multiple sclerosis

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

MedImmune to present ten abstracts at American Association for Cancer Research meeting

MedImmune to present ten abstracts at American Association for Cancer Research meeting

Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease

Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.